The FDA has issued an Emergency Use Authorization for Bimectin (ivermectin) injection to prevent New World screwworm infestations in certain cattle, expanding the number of products available to producers as U.S. officials work to protect livestock from the parasite.
Elanco Animal Health has completed a 25,000-square-foot expansion of its Elwood, Kansas, manufacturing facility, increasing production capacity by more than four times as the company scales its monoclonal antibody portfolio. Elanco has invested $120 million in the project and plans another $30 million through 2028.
Cronus Pharma has launched Robenacoxib Injection, the first FDA-approved generic bioequivalent to Onsior® (robenacoxib) Injection in the United States. The prescription NSAID provides veterinarians with another option for controlling postoperative pain and inflammation associated with specified surgical procedures in dogs and cats.
Dechra has launched Domidine™ (detomidine hydrochloride) in the United States, giving equine veterinarians another generic detomidine option for sedation and analgesia during minor surgical and diagnostic procedures. The product has been used internationally for more than a decade, according to the company.
Zoetis has received an FDA Emergency Use Authorization for Simparica Trio to treat New World screwworm infestations in dogs and puppies, expanding the animal health company’s response to the emerging parasite threat across companion animals and livestock.
The FDA has issued an Emergency Use Authorization for Elanco Animal Health’s CLiK Extra wound spray to help prevent New World screwworm infestations in multiple livestock and captive or captured wildlife species. The product is authorized for application on or around wounds but is not authorized to treat an active infestation.
American Regent Inc. Animal Health has initiated a nationwide recall of four lots of Adequan® injectable products after internal testing identified visible glass fibers in certain vials. The company said no adverse events have been reported to date.
Splash Beverage Group has expanded its exclusive global license for CannEpil® to include veterinary therapeutic applications, establishing a second FDA-regulated pharmaceutical development program alongside its existing human health program. The company plans to initially evaluate the cannabinoid-based formulation for companion animal oncology and chronic pain, with canine indications expected to be the first area of development.
The FDA’s Center for Veterinary Medicine has introduced a new pilot program aimed at strengthening domestic manufacturing of animal drugs and active pharmaceutical ingredients. The initiative offers regulatory incentives for companies that manufacture both drug products and their active ingredients in the United States to help improve supply chain resilience and reduce the risk of shortages.
Parnell has expanded its PropofolVet Multidose product line with a new 50 mL presentation, giving veterinary practices another option for canine anesthesia. The larger format is designed to improve workflow efficiency, optimize inventory management and reduce waste while complementing the company’s existing 20 mL offering.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.